{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:05:04Z","timestamp":1789571104320,"version":"build-2803163510"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06207-x","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:36:51Z","timestamp":1789569411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing Anticancer Drugs in Parkinson\u2019s Treatment: Molecular Pathways Driving Neuroprotection and Therapeutic Advancement"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4064-9625","authenticated-orcid":false,"given":"Poonam Laxman","family":"Bedage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4867-2079","authenticated-orcid":false,"given":"Yarava","family":"Dhanush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8838-4992","authenticated-orcid":false,"given":"Purnima","family":"Chettri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6547-9202","authenticated-orcid":false,"family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9817-9747","authenticated-orcid":false,"given":"Syed Sagheer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathi Doddla","family":"Raghunathanaidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"6207_CR1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:17013","journal-title":"Nat Rev Dis Primers"},{"key":"6207_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1498756","volume":"16","author":"Y Luo","year":"2024","unstructured":"Luo Y, Qiao L, Li M, Wen X, Zhang W, Li X (2024) Global, regional, national epidemiology and trends of Parkinson\u2019s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci 16. https:\/\/doi.org\/10.3389\/fnagi.2024.1498756","journal-title":"Front Aging Neurosci"},{"key":"6207_CR3","unstructured":"Braak H, Del Tredici K, R\u00fcb U, De Vos RA, Jansen Steur EN, Braak E (n.d.) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0197458002000659. Accessed 15 Jan 2026"},{"issue":"9996","key":"6207_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"key":"6207_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1468","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/nrd1468","journal-title":"Nat Rev Drug Discov"},{"key":"6207_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-025-04822-4","author":"Y Dhanush","year":"2025","unstructured":"Dhanush Y, Ganesh VS (2025) Non-oncologic to oncologic drug: a systematic review of drug repurposing in cancer. Cancer Chemother Pharmacol. https:\/\/doi.org\/10.1007\/s00280-025-04822-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"6207_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF03256811","volume":"24","author":"SH Sleigh","year":"2010","unstructured":"Sleigh SH, Barton CL (2010) Repurposing strategies for therapeutics. Pharm Med 24(3):151\u2013159. https:\/\/doi.org\/10.1007\/BF03256811","journal-title":"Pharm Med"},{"issue":"3","key":"6207_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JPD-160867","volume":"6","author":"F Pagan","year":"2016","unstructured":"Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, Wilmarth BM (2016) Nilotinib effects in Parkinson\u2019s disease and dementia with Lewy bodies. J Parkinsons Dis 6(3):503\u201317. https:\/\/doi.org\/10.3233\/JPD-160867","journal-title":"J Parkinsons Dis"},{"key":"6207_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.996217","author":"X Xie","year":"2022","unstructured":"Xie X, Yuan P, Kou L, Chen X, Li J, Li Y (2022) Nilotinib in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.996217","journal-title":"Front Aging Neurosci"},{"key":"6207_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2010.08.028","author":"A Ghosh","year":"2010","unstructured":"Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, Kanthasamy A (2010) Neuroprotection by a mitochondria-targeted drug in a Parkinson\u2019s disease model. Free Radic Biol Med. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2010.08.028","journal-title":"Free Radic Biol Med"},{"key":"6207_CR11","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20080063","author":"MF Ross","year":"2008","unstructured":"Ross MF, Prime TA, Abakumova I, James AM, Porteous CM, Smith RAJ, Murphy MP (2008) Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem J. https:\/\/doi.org\/10.1042\/BJ20080063","journal-title":"Biochem J"},{"issue":"3","key":"6207_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/mds.28389","volume":"36","author":"FL Pagan","year":"2021","unstructured":"Pagan FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, Mulki S, Ferrante D, Matar S, Ahn J (2021) Long-term safety and clinical effects of nilotinib in Parkinson\u2019s disease. Mov Disord 36(3):740\u20139. https:\/\/doi.org\/10.1002\/mds.28389","journal-title":"Mov Disord"},{"key":"6207_CR13","doi-asserted-by":"publisher","unstructured":"Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, D\u2019Uva G (2022) Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med 9. https:\/\/doi.org\/10.3389\/fcvm.2022.847012","DOI":"10.3389\/fcvm.2022.847012"},{"key":"6207_CR14","doi-asserted-by":"publisher","unstructured":"Bidgoli N, Salemi MH, Sadi FH, Farrokhi Z, Abbaszadeh S, Foroozandeh E (2025) Risk of colorectal cancer in Parkinson\u2019s disease: a systematic review and meta-analysis of 11 million participants. BMC Neurol 25(1). https:\/\/doi.org\/10.1186\/s12883-025-04206-4","DOI":"10.1186\/s12883-025-04206-4"},{"key":"6207_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00544-7","author":"JM Taymans","year":"2023","unstructured":"Taymans JM, Fell M, Greenamyre T, Hirst WD, Mamais A, Padmanabhan S, Peter I (2023) Perspective on the current state of the LRRK2 field. NPJ Parkinsons Dis. https:\/\/doi.org\/10.1038\/s41531-023-00544-7","journal-title":"NPJ Parkinsons Dis"},{"key":"6207_CR16","doi-asserted-by":"publisher","unstructured":"Pinzi L, Bisi N, Rastelli G (2024) How drug repurposing can advance drug discovery: challenges and opportunities. Front Drug Discov 4. https:\/\/doi.org\/10.3389\/fddsv.2024.1460100","DOI":"10.3389\/fddsv.2024.1460100"},{"issue":"5","key":"6207_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10552-009-9497-6","volume":"21","author":"A Bajaj","year":"2010","unstructured":"Bajaj A, Driver JA, Schernhammer ES (2010) Parkinson\u2019s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 21(5):697\u2013707. https:\/\/doi.org\/10.1007\/s10552-009-9497-6","journal-title":"Cancer Causes Control"},{"key":"6207_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8100416","author":"M Ejma","year":"2020","unstructured":"Ejma M, Madetko N, Brzecka A, Guranski K, Alster P, Misiuk-Hoj\u0142o M, Somasundaram SG (2020) The links between Parkinson\u2019s disease and cancer. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines8100416","journal-title":"Biomedicines"},{"key":"6207_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1749-6632.2008.03681.x","volume":"1155","author":"M D\u2019Amelio","year":"2009","unstructured":"D\u2019Amelio M, Ragonese P, Sconzo G, Aridon P, Savettieri G (2009) Parkinson\u2019s disease and cancer: insights for pathogenesis from epidemiology. Ann N Y Acad Sci 1155:324\u201334. https:\/\/doi.org\/10.1111\/j.1749-6632.2008.03681.x","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"6207_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00367-7","volume":"15","author":"P Ge","year":"2020","unstructured":"Ge P, Dawson VL, Dawson TM (2020) PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson\u2019s disease. Mol Neurodegener 15(1). https:\/\/doi.org\/10.1186\/s13024-020-00367-7","journal-title":"Mol Neurodegener"},{"issue":"12","key":"6207_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125782","volume":"26","author":"S Castelli","year":"2025","unstructured":"Castelli S, Carinci E, Baldelli S (2025) Oxidative stress in neurodegenerative disorders: a key driver in impairing skeletal muscle health. Int J Mol Sci 26(12). https:\/\/doi.org\/10.3390\/ijms26125782","journal-title":"Int J Mol Sci"},{"key":"6207_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.12.007","author":"AM Pickrell","year":"2015","unstructured":"Pickrell AM, Youle RJ (2015) The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease. Neuron. https:\/\/doi.org\/10.1016\/j.neuron.2014.12.007","journal-title":"Neuron"},{"key":"6207_CR23","doi-asserted-by":"publisher","unstructured":"Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4(11). https:\/\/doi.org\/10.1038\/ncpneuro0924","DOI":"10.1038\/ncpneuro0924"},{"issue":"1-2","key":"6207_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","volume":"176","author":"B Levine","year":"2019","unstructured":"Levine B, Kroemer G (2019) Biological functions of autophagy genes: a disease perspective. Cell 176(1\u20132):11\u201342. https:\/\/doi.org\/10.1016\/j.cell.2018.09.048","journal-title":"Cell"},{"issue":"14","key":"6207_CR25","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00018-019-03428-3","volume":"77","author":"J Seo","year":"2019","unstructured":"Seo J, Park M (2019) Molecular crosstalk between cancer and neurodegenerative diseases. Cell Mol Life Sci 77(14):2659\u201380. https:\/\/doi.org\/10.1007\/s00018-019-03428-3","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"6207_CR26","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/ejn.14290","volume":"49","author":"MG Tansey","year":"2019","unstructured":"Tansey MG, Romero-Ramos M (2019) Immune system responses in Parkinson\u2019s disease: early and dynamic. Eur J Neurosci 49(3):364\u201383. https:\/\/doi.org\/10.1111\/ejn.14290","journal-title":"Eur J Neurosci"},{"issue":"1","key":"6207_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI (2019) Inflammation and cancer: triggers, mechanisms, and consequences. Immun 51(1):27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025","journal-title":"Immun"},{"issue":"1","key":"6207_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","volume":"246","author":"JA DiDonato","year":"2012","unstructured":"DiDonato JA, Mercurio F, Karin M (2012) NF-\u03baB and the link between inflammation and cancer. Immunol Rev 246(1):379\u2013400. https:\/\/doi.org\/10.1111\/j.1600-065X.2012.01099.x","journal-title":"Immunol Rev"},{"issue":"1","key":"6207_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01062-w","volume":"8","author":"PMJ Quinn","year":"2020","unstructured":"Quinn PMJ, Moreira PI, Ambr\u00f3sio AF, Alves CH (2020) PINK1\/PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathol Commun 8(1). https:\/\/doi.org\/10.1186\/s40478-020-01062-w","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"6207_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","volume":"8","author":"X Dong-Chen","year":"2023","unstructured":"Dong-Chen X, Yong C, Yang X, Chen-Yu ST, Li-Hua P (2023) Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8(1):73. https:\/\/doi.org\/10.1038\/s41392-023-01353-3","journal-title":"Signal Transduct Target Ther"},{"key":"6207_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104841","author":"D Advani","year":"2020","unstructured":"Advani D, Gupta R, Tripathi R, Sharma S, Ambasta RK, Kumar P (2020) Protective role of anticancer drugs in neurodegenerative disorders: a drug repurposing approach. Neurochem Int. https:\/\/doi.org\/10.1016\/j.neuint.2020.104841","journal-title":"Neurochem Int"},{"key":"6207_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073899","author":"A Surguchov","year":"2024","unstructured":"Surguchov A, Surguchov AA (2024) Association between Parkinson\u2019s disease and cancer: new findings and possible mediators. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25073899","journal-title":"Int J Mol Sci"},{"issue":"4","key":"6207_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/ana.20624","volume":"58","author":"MF Beal","year":"2005","unstructured":"Beal MF (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58(4):495\u2013505. https:\/\/doi.org\/10.1002\/ana.20624","journal-title":"Ann Neurol"},{"issue":"3","key":"6207_CR34","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","volume":"54","author":"AHV Schapira","year":"1989","unstructured":"Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson\u2019s disease. J Neurochem 54(3):823\u2013827. https:\/\/doi.org\/10.1111\/j.1471-4159.1990.tb02325.x","journal-title":"J Neurochem"},{"issue":"6","key":"6207_CR35","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/j.1471-4159.2006.04333.x","volume":"100","author":"TB Sherer","year":"2007","unstructured":"Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A (2007) Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson\u2019s disease. J Neurochem 100(6):1469\u201379. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04333.x","journal-title":"J Neurochem"},{"key":"6207_CR36","doi-asserted-by":"publisher","DOI":"10.1101\/gad.262758.115","author":"TM Durcan","year":"2015","unstructured":"Durcan TM, Fon EA (2015) The three P\u2019s of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes Dev. https:\/\/doi.org\/10.1101\/gad.262758.115","journal-title":"Genes Dev"},{"issue":"5930","key":"6207_CR37","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029\u201333. https:\/\/doi.org\/10.1126\/science.1160809","journal-title":"Science"},{"key":"6207_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3038","author":"WH Koppenol","year":"2011","unstructured":"Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg\u2019s contributions to current concepts of cancer metabolism. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/nrc3038","journal-title":"Nat Rev Cancer"},{"key":"6207_CR39","doi-asserted-by":"crossref","unstructured":"Matsuda S, Nakanishi A, Minami A, Wada Y, Kitagishi Y (2015) Functions and characteristics of PINK1 and Parkin in cancer. Front Biosci [cited 2026 Jun 27]. Available from: https:\/\/storage.imrpress.com\/imr\/journal\/FBL\/article\/491200\/1752762938554.pdf. Accessed 16 Jan 2026","DOI":"10.2741\/4321"},{"key":"6207_CR40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.ra117.001469","author":"KA Boyle","year":"2018","unstructured":"Boyle KA, Van Wickle J, Hill RB, Marchese A, Kalyanaraman B, Dwinell MB (2018) Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.ra117.001469","journal-title":"J Biol Chem"},{"issue":"19","key":"6207_CR41","doi-asserted-by":"publisher","first-page":"8788","DOI":"10.1073\/pnas.1003428107","volume":"107","author":"F Weinberg","year":"2010","unstructured":"Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107(19):8788\u201393. https:\/\/doi.org\/10.1073\/pnas.1003428107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6207_CR42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2534","author":"G Cheng","year":"2016","unstructured":"Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K, Barrios CS, Weber JJ (2016) Mitochondria-targeted analogues of metformin exhibit enhanced antiproliferative and radiosensitizing effects in pancreatic cancer cells. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2534","journal-title":"Cancer Res"},{"key":"6207_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.302","author":"JP Bernardini","year":"2017","unstructured":"Bernardini JP, Lazarou M, Dewson G (2017) Parkin and mitophagy in cancer. Oncogene. https:\/\/doi.org\/10.1038\/onc.2016.302","journal-title":"Oncogene"},{"key":"6207_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.174","author":"MP Murphy","year":"2018","unstructured":"Murphy MP, Hartley RC (2018) Mitochondria as a therapeutic target for common pathologies. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/nrd.2018.174","journal-title":"Nat Rev Drug Discov"},{"key":"6207_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-241","volume":"9","author":"A Ghosh","year":"2012","unstructured":"Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP (2012) Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson\u2019s disease. J Neuroinflammation 9. https:\/\/doi.org\/10.1186\/1742-2094-9-241","journal-title":"J Neuroinflammation"},{"issue":"15","key":"6207_CR46","doi-asserted-by":"publisher","first-page":"10043","DOI":"10.1021\/acs.chemrev.7b00042","volume":"117","author":"J Zielonka","year":"2017","unstructured":"Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, Cheng G, Lopez M (2017) Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev 117(15):10043\u201310120. https:\/\/doi.org\/10.1021\/acs.chemrev.7b00042","journal-title":"Chem Rev"},{"issue":"Jul","key":"6207_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00400","volume":"9","author":"C Rotermund","year":"2018","unstructured":"Rotermund C, Machetanz G, Fitzgerald JC (2018) The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol (Lausanne) 9(Jul). https:\/\/doi.org\/10.3389\/fendo.2018.00400","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6207_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00027-3","author":"S Kordes","year":"2015","unstructured":"Kordes S, Pollak MN, Zwinderman AH, Math\u00f4t RA, Weterman MJ, Beeker A, Punt CJ (2015) Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(15)00027-3","journal-title":"Lancet Oncol"},{"key":"6207_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx202","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Zimprich A, Carvajal Berrio DA, Schindler KM, Maurer B, Schulte C, Bus C (2017) Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson\u2019s disease. Brain. https:\/\/doi.org\/10.1093\/brain\/awx202","journal-title":"Brain"},{"issue":"6","key":"6207_CR50","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","volume":"67","author":"HC Cheng","year":"2010","unstructured":"Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67(6):715\u2013725. https:\/\/doi.org\/10.1002\/ana.21995","journal-title":"Ann Neurol"},{"key":"6207_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2009.01.012","author":"C Cook","year":"2009","unstructured":"Cook C, Petrucelli L (2009) A critical evaluation of the ubiquitin-proteasome system in Parkinson\u2019s disease. Biochim Biophys Acta. https:\/\/doi.org\/10.1016\/j.bbadis.2009.01.012","journal-title":"Biochim Biophys Acta"},{"key":"6207_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ng.491","author":"S Veeriah","year":"2010","unstructured":"Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N (2010) Somatic mutations of the Parkinson\u2019s disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. https:\/\/doi.org\/10.1038\/ng.491","journal-title":"Nat Genet"},{"key":"6207_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/s0304-3940(00)01701-8","author":"KSP McNaught","year":"2001","unstructured":"McNaught KSP, Jenner P (2001) Proteasomal function is impaired in substantia nigra in Parkinson\u2019s disease. Neurosci Lett. https:\/\/doi.org\/10.1016\/s0304-3940(00)01701-8","journal-title":"Neurosci Lett"},{"key":"6207_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.08.021","author":"R Betarbet","year":"2005","unstructured":"Betarbet R, Sherer TB, Greenamyre JT (2005) Ubiquitin-proteasome system and Parkinson\u2019s diseases. Exp Neurol. https:\/\/doi.org\/10.1016\/j.expneurol.2004.08.021","journal-title":"Exp Neurol"},{"key":"6207_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.12.021","author":"EJ Bennett","year":"2005","unstructured":"Bennett EJ, Bence NF, Jayakumar R, Kopito RR (2005) Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell. https:\/\/doi.org\/10.1016\/j.molcel.2004.12.021","journal-title":"Mol Cell"},{"key":"6207_CR56","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m300227200","author":"JL Webb","year":"2003","unstructured":"Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) \u03b1-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.m300227200","journal-title":"J Biol Chem"},{"key":"6207_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/77060","author":"H Shimura","year":"2000","unstructured":"Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. https:\/\/doi.org\/10.1038\/77060","journal-title":"Nat Genet"},{"issue":"24","key":"6207_CR58","doi-asserted-by":"publisher","first-page":"13354","DOI":"10.1073\/pnas.240347797","volume":"97","author":"Y Zhang","year":"2000","unstructured":"Zhang Y, Gao J, Chung KKK, Huang H, Dawson VL, Dawson TM (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 97(24):13354\u20139. https:\/\/doi.org\/10.1073\/pnas.240347797","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6207_CR59","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200809125","author":"D Narendra","year":"2008","unstructured":"Narendra D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. https:\/\/doi.org\/10.1083\/jcb.200809125","journal-title":"J Cell Biol"},{"key":"6207_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2018.01.004","author":"S Pickles","year":"2018","unstructured":"Pickles S, Vigi\u00e9 P, Youle RJ (2018) Mitophagy and quality control mechanisms in mitochondrial maintenance. Curr Biol. https:\/\/doi.org\/10.1016\/j.cub.2018.01.004","journal-title":"Curr Biol"},{"issue":"1","key":"6207_CR61","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1471-4159.2000.0750436.x","volume":"75","author":"JN Keller","year":"2000","unstructured":"Keller JN, Hanni KB, Markesbery WR (2000) Impaired proteasome function in Alzheimer\u2019s disease. J Neurochem 75(1):436\u2013439. https:\/\/doi.org\/10.1046\/j.1471-4159.2000.0750436.x","journal-title":"J Neurochem"},{"key":"6207_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)00296-3","author":"KSP McNaught","year":"2002","unstructured":"McNaught KSP, Belizaire R, Jenner P, Olanow CW, Isacson O (2002) Selective loss of 20S proteasome \u03b1-subunits in the substantia nigra pars compacta in Parkinson\u2019s disease. Neurosci Lett. https:\/\/doi.org\/10.1016\/S0304-3940(02)00296-3","journal-title":"Neurosci Lett"},{"key":"6207_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113910","author":"A Sharma","year":"2020","unstructured":"Sharma A, Liu H, Tobar-Tosse F, Chand Dakal T, Ludwig M, Holz FG, Loeffler KU, W\u00fcllner U (2020) Ubiquitin carboxyl-terminal hydrolases (UCHs): potential mediators for cancer and neurodegeneration. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21113910","journal-title":"Int J Mol Sci"},{"key":"6207_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-0804-9","author":"A Keo","year":"2020","unstructured":"Keo A, Mahfouz A, Ingrassia AMT, Meneboo JP, Villenet C, Mutez E, Comptdaer T (2020) Transcriptomic signatures of brain regional vulnerability to Parkinson\u2019s disease. Commun Biol. https:\/\/doi.org\/10.1038\/s42003-020-0804-9","journal-title":"Commun Biol"},{"issue":"17","key":"6207_CR65","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1516282","journal-title":"N Engl J Med"},{"issue":"7","key":"6207_CR66","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2014-01","volume":"124","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D (2014) Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients. Blood 124(7):1038\u20131046. https:\/\/doi.org\/10.1182\/blood-2014-01","journal-title":"Blood"},{"key":"6207_CR67","doi-asserted-by":"publisher","unstructured":"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y et al (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2766","DOI":"10.1158\/0008-5472.CAN-09-2766"},{"key":"6207_CR68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0636","author":"EC Lee","year":"2011","unstructured":"Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP (2011) Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0636","journal-title":"Clin Cancer Res"},{"key":"6207_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2015.08.030","author":"L Zhang","year":"2015","unstructured":"Zhang L, Wang K, Lei Y, Li Q, Nice EC, Huang C (2015) Redox signaling: potential arbitrator of autophagy and apoptosis in therapeutic response. Free Radic Biol Med. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.08.030","journal-title":"Free Radic Biol Med"},{"key":"6207_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/nature05853","author":"UB Pandey","year":"2007","unstructured":"Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP (2007) HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. https:\/\/doi.org\/10.1038\/nature05853","journal-title":"Nature"},{"key":"6207_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4011","author":"N Myeku","year":"2016","unstructured":"Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, Duff KE (2016) Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med. https:\/\/doi.org\/10.1038\/nm.4011","journal-title":"Nat Med"},{"key":"6207_CR72","unstructured":"Bedford L, Paine S, Sheppard PW, Mayer RJ, Roelofs J. Assembly, structure and function of the 26S proteasome [Internet]. [cited 2026 Jun 29]. Available from: https:\/\/www.academia.edu\/download\/48694459\/Assembly_structure_and_function_of_the_220160909-8326-12e4xbv.pdf. Accessed 15 Jan 2026"},{"issue":"Apr","key":"6207_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00185","volume":"11","author":"A Ciechanover","year":"2017","unstructured":"Ciechanover A, Kwon YT (2017) Protein quality control by molecular chaperones in neurodegeneration. Front Neurosci 11(Apr). https:\/\/doi.org\/10.3389\/fnins.2017.00185","journal-title":"Front Neurosci"},{"key":"6207_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.07.030","author":"DC Rubinsztein","year":"2011","unstructured":"Rubinsztein DC, Mari\u00f1o G, Kroemer G (2011) Autophagy and aging. Cell. https:\/\/doi.org\/10.1016\/j.cell.2011.07.030","journal-title":"Cell"},{"key":"6207_CR75","doi-asserted-by":"publisher","unstructured":"Levine B, Packer M, Codogno P (2015) Development of autophagy inducers in clinical medicine. J Clin Invest [Internet].\u00a0https:\/\/doi.org\/10.1172\/JCI73938DS1","DOI":"10.1172\/JCI73938DS1"},{"key":"6207_CR76","unstructured":"Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC (n.d.) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and \u03b1-synuclein. J Biol Chem [Internet]. [cited 2026 Jun 29]. Available from: https:\/\/www.jbc.org\/article\/S0021-9258(20)68860-3\/fulltext. Accessed 19 Jan 2026"},{"key":"6207_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2013.08.012","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Finley D (2014) Regulation of proteasome activity in health and disease. Biochim Biophys Acta. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.08.012","journal-title":"Biochim Biophys Acta"},{"key":"6207_CR78","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/978-1-59259-767-3_41","volume-title":"Cancer Chemoprevention: Promising Cancer Chemopreventive Agents","author":"J Adams","year":"2004","unstructured":"Adams J (2004) Proteasome inhibitors in cancer therapy. Cancer Chemoprevention: Promising Cancer Chemopreventive Agents. Springer, New York, pp 635\u201342. https:\/\/doi.org\/10.1007\/978-1-59259-767-3_41"},{"key":"6207_CR79","doi-asserted-by":"crossref","unstructured":"Kisselev AF, van der Linden WA, Overkleeft HS (2012) Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol [Internet]. [cited 2026 Jun 29]. Available from: https:\/\/www.cell.com\/ccbio\/fulltext\/S1074-5521(12)00012-9. Accessed 2 Feb 2026","DOI":"10.1016\/j.chembiol.2012.01.003"},{"issue":"2","key":"6207_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12079-011-0121-7","volume":"5","author":"LJ Crawford","year":"2011","unstructured":"Crawford LJ, Walker B, Irvine AE (2011) Proteasome inhibitors in cancer therapy. J Cell Commun Signal 5(2):101\u2013110. https:\/\/doi.org\/10.1007\/s12079-011-0121-7","journal-title":"J Cell Commun Signal"},{"key":"6207_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05672-9","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"issue":"1","key":"6207_CR82","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00109-013-1107-0","volume":"92","author":"L Xu","year":"2014","unstructured":"Xu L, Lin DC, Yin D, Koeffler HP (2014) An emerging role of PARK2 in cancer. J Mol Med (Berl) 92(1):31\u201342. https:\/\/doi.org\/10.1007\/s00109-013-1107-0","journal-title":"J Mol Med (Berl)"},{"key":"6207_CR83","doi-asserted-by":"publisher","unstructured":"Feng DD, Cai W, Chen X (2015) The associations between Parkinson\u2019s disease and cancer: the plot thickens. Transl Neurodegener 4(1). https:\/\/doi.org\/10.1186\/s40035-015-0043-z","DOI":"10.1186\/s40035-015-0043-z"},{"issue":"23","key":"6207_CR84","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1212\/WNL.0b013e31821e554e","volume":"76","author":"R Liu","year":"2011","unstructured":"Liu R, Gao X, Lu Y, Chen H (2011) Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 76(23):2002\u20132009. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e554e","journal-title":"Neurology"},{"issue":"6","key":"6207_CR85","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125(6):795\u2013813. https:\/\/doi.org\/10.1007\/s00401-013-1114-9","journal-title":"Acta Neuropathol"},{"key":"6207_CR86","doi-asserted-by":"crossref","unstructured":"Hebron ML, Lonskaya I, Moussa CEH (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models. Hum Mol Genet [Internet]. [cited 2026 Jun 29]. Available from: https:\/\/academic.oup.com\/hmg\/article-abstract\/22\/16\/3315\/627350. Accessed 1 Feb 2026","DOI":"10.1093\/hmg\/ddt192"},{"issue":"3","key":"6207_CR87","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","volume":"78","author":"T Simuni","year":"2021","unstructured":"Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C et al (2021) Efficacy of nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial. JAMA Neurol 78(3):312\u2013320. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4725","journal-title":"JAMA Neurol"},{"key":"6207_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/nm850","author":"SS Gill","year":"2003","unstructured":"Gill SS, Patel NK, Hotton GR, O\u2019Sullivan K, McCarter R, Bunnage M, Brooks DJ (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. https:\/\/doi.org\/10.1038\/nm850","journal-title":"Nat Med"},{"key":"6207_CR89","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009431","author":"PG Coune","year":"2012","unstructured":"Coune PG, Schneider BL, Aebischer P (2012) Parkinson\u2019s disease: gene therapies. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a009431","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6207_CR90","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2016.06.12","author":"AA Calinescu","year":"2016","unstructured":"Calinescu AA, Castro MG (2016) Microtubule targeting agents in glioma. Transl Cancer Res. https:\/\/doi.org\/10.21037\/tcr.2016.06.12","journal-title":"Transl Cancer Res"},{"key":"6207_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2010.10.054","author":"Y Jiang","year":"2011","unstructured":"Jiang Y, Wei N, Lu T, Zhu J, Xu G, Liu X (2011) Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience. https:\/\/doi.org\/10.1016\/j.neuroscience.2010.10.054","journal-title":"Neuroscience"},{"key":"6207_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/s0301-0082(00)00014-9","author":"MG Murer","year":"2001","unstructured":"Murer MG, Yan Q, Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer\u2019s disease and Parkinson\u2019s disease. Prog Neurobiol. https:\/\/doi.org\/10.1016\/s0301-0082(00)00014-9","journal-title":"Prog Neurobiol"},{"key":"6207_CR93","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah3374","author":"X Mao","year":"2016","unstructured":"Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE (2016) Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. https:\/\/doi.org\/10.1126\/science.aah3374","journal-title":"Science"},{"issue":"s2","key":"6207_CR94","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JPD-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer P, Van Den Berge N (2019) Brain-first versus gut-first Parkinson\u2019s disease: a hypothesis. J Parkinsons Dis 9(s2):S281-95. https:\/\/doi.org\/10.3233\/JPD-191721","journal-title":"J Parkinsons Dis"},{"key":"6207_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00797-1","author":"G Kuo","year":"2025","unstructured":"Kuo G, Kumbhar R, Blair W, Dawson VL, Dawson TM, Mao X (2025) Emerging targets of \u03b1-synuclein spreading in \u03b1-synucleinopathies: a review of mechanistic pathways and interventions. Mol Neurodegener. https:\/\/doi.org\/10.1186\/s13024-025-00797-1","journal-title":"Mol Neurodegener"},{"issue":"1","key":"6207_CR96","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E et al (2022) Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970","journal-title":"N Engl J Med"},{"key":"6207_CR97","doi-asserted-by":"publisher","unstructured":"Bondarenko O, Saarma M (2021) Neurotrophic factors in Parkinson\u2019s disease: clinical trials, open challenges and nanoparticle-mediated delivery to the brain. Front Cell Neurosci 15. https:\/\/doi.org\/10.3389\/fncel.2021.682597","DOI":"10.3389\/fncel.2021.682597"},{"key":"6207_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.593572","author":"FP Manfredsson","year":"2020","unstructured":"Manfredsson FP, Polinski NK, Subramanian T, Boulis N, Wakeman DR, Mandel RJ (2020) The future of GDNF in Parkinson\u2019s disease. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2020.593572","journal-title":"Front Aging Neurosci"},{"key":"6207_CR99","doi-asserted-by":"publisher","unstructured":"Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D (2019) Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson\u2019s disease. Brain [Internet].\u00a0https:\/\/doi.org\/10.1093\/brain\/awy379","DOI":"10.1093\/brain\/awy379"},{"key":"6207_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics5010127","author":"C G\u00e9ral","year":"2013","unstructured":"G\u00e9ral C, Angelova A, Lesieur S (2013) From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF). Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics5010127","journal-title":"Pharmaceutics"},{"key":"6207_CR101","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2026.2647033","author":"V Evola","year":"2026","unstructured":"Evola V, Parmar MS (2026) Gene therapy for Parkinson\u2019s disease: current landscape, translational challenges, and future directions. Expert Rev Neurother. https:\/\/doi.org\/10.1080\/14737175.2026.2647033","journal-title":"Expert Rev Neurother"},{"key":"6207_CR102","doi-asserted-by":"publisher","unstructured":"Mao X, Gu H, Kim D, Kimura Y, Wang N, Xu E, Kumbhar R, Ming X (2024) Aplp1 interacts with Lag3 to facilitate transmission of pathologic \u03b1-synuclein. Nat Commun 15(1). https:\/\/doi.org\/10.1038\/s41467-024-49016-3","DOI":"10.1038\/s41467-024-49016-3"},{"key":"6207_CR103","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1788-16.2017","author":"P Brundin","year":"2017","unstructured":"Brundin P, Melki R (2017) Prying into the prion hypothesis for Parkinson\u2019s disease. J Neurosci. https:\/\/doi.org\/10.1523\/JNEUROSCI.1788-16.2017","journal-title":"J Neurosci"},{"issue":"6","key":"6207_CR104","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ana.24802","volume":"80","author":"R Inzelberg","year":"2016","unstructured":"Inzelberg R, Flash S, Friedman E, Azizi E (2016) Cutaneous malignant melanoma and Parkinson disease: common pathways? Ann Neurol 80(6):811\u2013820. https:\/\/doi.org\/10.1002\/ana.24802","journal-title":"Ann Neurol"},{"key":"6207_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1432373","author":"C Tang","year":"2024","unstructured":"Tang C, Fu P, Lin L, Zhou H, Huang Y, Li Y, Zhao S (2024) Causal association between Parkinson\u2019s disease and cancer: a bidirectional Mendelian randomization study. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2024.1432373","journal-title":"Front Aging Neurosci"},{"key":"6207_CR106","doi-asserted-by":"crossref","unstructured":"Qing H, Wong W, McGeer EG, McGeer PL (2009) Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun [Internet]. [cited 2026 Jun 29]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006291X09013114. Accessed 15 Feb 2026","DOI":"10.1016\/S1353-8020(09)70755-2"},{"key":"6207_CR107","doi-asserted-by":"publisher","unstructured":"O\u2019Hara DM, Pawar G, Kalia SK, Kalia LV (2020) LRRK2 and \u03b1-synuclein: distinct or synergistic players in Parkinson\u2019s disease? Front Neurosci 14. https:\/\/doi.org\/10.3389\/fnins.2020.00577","DOI":"10.3389\/fnins.2020.00577"},{"key":"6207_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2016.12.006","author":"Y Gong","year":"2017","unstructured":"Gong Y, Schumacher SE, Wu WH, Tang F, Beroukhim R, Chan TA (2017) Pan-cancer analysis links PARK2 to BCL-XL-dependent control of apoptosis. Neoplasia. https:\/\/doi.org\/10.1016\/j.neo.2016.12.006","journal-title":"Neoplasia"},{"issue":"4","key":"6207_CR109","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10517-021-05242-z","volume":"171","author":"AB Pupyshev","year":"2021","unstructured":"Pupyshev AB, Tenditnik MV, Ovsyukova MV, Akopyan AA, Dubrovina NI, Tikhonova MA (2021) Restoration of Parkinson\u2019s disease-like deficits by activating autophagy through mTOR-dependent and mTOR-independent mechanisms in pharmacological and transgenic models. Bull Exp Biol Med 171(4):425\u2013430. https:\/\/doi.org\/10.1007\/s10517-021-05242-z","journal-title":"Bull Exp Biol Med"},{"key":"6207_CR110","doi-asserted-by":"publisher","unstructured":"Lee HJ, Yoon YS, Lee SJ (2018) Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction. Cell Death Dis [Internet].\u00a0https:\/\/doi.org\/10.1038\/s41419-018-0749-9","DOI":"10.1038\/s41419-018-0749-9"},{"issue":"12","key":"6207_CR111","doi-asserted-by":"publisher","first-page":"7253","DOI":"10.1007\/s12035-023-03530-5","volume":"60","author":"Y Gopar-Cuevas","year":"2023","unstructured":"Gopar-Cuevas Y, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Rodriguez-Rocha H, Garcia-Garcia A (2023) Metformin and trehalose-modulated autophagy exerts a neurotherapeutic effect on Parkinson\u2019s disease. Mol Neurobiol 60(12):7253\u20137273. https:\/\/doi.org\/10.1007\/s12035-023-03530-5","journal-title":"Mol Neurobiol"},{"issue":"6","key":"6207_CR112","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s12272-022-01386-2","volume":"45","author":"SH Moon","year":"2022","unstructured":"Moon SH, Kwon Y, Huh YE, Choi HJ (2022) Trehalose ameliorates prodromal non-motor deficits and aberrant protein accumulation in a rotenone-induced mouse model of Parkinson\u2019s disease. Arch Pharm Res 45(6):417\u201332. https:\/\/doi.org\/10.1007\/s12272-022-01386-2","journal-title":"Arch Pharm Res"},{"key":"6207_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040857","author":"A Cunha","year":"2022","unstructured":"Cunha A, Gaubert A, Verget J, Thiolat ML, Barth\u00e9l\u00e9my P, Latxague L, Dehay B (2022) Trehalose-based nucleolipids as nanocarriers for autophagy modulation: an in vitro study. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14040857","journal-title":"Pharmaceutics"},{"key":"6207_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175875","author":"HM Mansour","year":"2023","unstructured":"Mansour HM, Mohamed AF, Khattab MM, El-Khatib AS (2023) Lapatinib ditosylate rescues motor deficits in rotenone-intoxicated rats: potential repurposing of anti-cancer drug as a disease-modifying agent in Parkinson\u2019s disease. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175875","journal-title":"Eur J Pharmacol"},{"issue":"14","key":"6207_CR115","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1021\/acschemneuro.1c00144","volume":"12","author":"V Kakoty","year":"2021","unstructured":"Kakoty V, KC S, Dubey SK, Yang CH, Taliyan R (2021) Neuroprotective effects of trehalose and sodium butyrate on preformed fibrillar form of \u03b1-synuclein-induced rat model of Parkinson\u2019s disease. ACS Chem Neurosci 12(14):2643\u201360. https:\/\/doi.org\/10.1021\/acschemneuro.1c00144","journal-title":"ACS Chem Neurosci"},{"key":"6207_CR116","doi-asserted-by":"publisher","unstructured":"Saito Y, Saito H (2012) MicroRNAs in cancers and neurodegenerative disorders. Front Genet 3(Sep). https:\/\/doi.org\/10.3389\/fgene.2012.00194","DOI":"10.3389\/fgene.2012.00194"},{"issue":"9","key":"6207_CR117","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1021\/pr400302w","volume":"12","author":"CW Hu","year":"2013","unstructured":"Hu CW, Tseng CW, Chien CW, Huang HC, Ku WC, Lee SJ, Chen YJ, Juan HF (2013) Quantitative proteomics reveals diverse roles of miR-148a from gastric cancer progression to neurological development. J Proteome Res 12(9):3993\u20134004. https:\/\/doi.org\/10.1021\/pr400302w","journal-title":"J Proteome Res"},{"issue":"2","key":"6207_CR118","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","volume":"35","author":"MS Beg","year":"2017","unstructured":"Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG (2017) Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 35(2):180\u20138. https:\/\/doi.org\/10.1007\/s10637-016-0407-y","journal-title":"Invest New Drugs"},{"key":"6207_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0802-1","author":"DS Hong","year":"2020","unstructured":"Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL (2020) Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. https:\/\/doi.org\/10.1038\/s41416-020-0802-1","journal-title":"Br J Cancer"},{"issue":"3","key":"6207_CR120","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1021\/ac403044t","volume":"86","author":"K Kelnar","year":"2014","unstructured":"Kelnar K, Peltier HJ, Leatherbury N, Stoudemire J, Bader AG (2014) Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal Chem 86(3):1534\u201342. https:\/\/doi.org\/10.1021\/ac403044t","journal-title":"Anal Chem"},{"issue":"12","key":"6207_CR121","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/gm516","volume":"5","author":"C Stahlhut","year":"2013","unstructured":"Stahlhut C, Slack FJ (2013) MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med 5(12):111. https:\/\/doi.org\/10.1186\/gm516","journal-title":"Genome Med"},{"key":"6207_CR122","doi-asserted-by":"publisher","unstructured":"Shaheen N, Shaheen A, Osama M, Nashwan AJ, Bharmauria V, Flouty O (2024) MicroRNAs regulation in Parkinson\u2019s disease, and their potential role as diagnostic and therapeutic targets. NPJ Parkinsons Dis [Internet]. https:\/\/doi.org\/10.1038\/s41531-024-00791-2","DOI":"10.1038\/s41531-024-00791-2"},{"key":"6207_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2025.01.038","author":"D Zheng","year":"2025","unstructured":"Zheng D, Chen J (2025) MicroRNAs in Parkinson\u2019s disease: from pathogenesis to diagnostics and therapeutic strategies. Neuroscience. https:\/\/doi.org\/10.1016\/j.neuroscience.2025.01.038","journal-title":"Neuroscience"},{"issue":"3","key":"6207_CR124","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1007\/s10753-024-02125-z","volume":"48","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, Muhammad FA, Singh A, Mustafa MA, Al Zuhairi RAH, Ghildiyal P, Hashim G (2025) MicroRNAs modulating neuroinflammation in Parkinson\u2019s disease. Inflammation 48(3):1042\u201362. https:\/\/doi.org\/10.1007\/s10753-024-02125-z","journal-title":"Inflammation"},{"key":"6207_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262412164","author":"M Chrysanthou","year":"2025","unstructured":"Chrysanthou M, Christodoulou CC, Papanicolaou EZ (2025) The role of miRNAs in Parkinson\u2019s disease: a systematic review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms262412164","journal-title":"Int J Mol Sci"},{"key":"6207_CR126","doi-asserted-by":"publisher","first-page":"1704976","DOI":"10.3389\/fneur.2025.1704976","volume":"16","author":"N Jung","year":"2025","unstructured":"Jung N, Kim SN, Laffita Mesa J, Rojas Torres J, Mart\u00ednez Dur\u00e1n LM (2025) Cross-species validation of a 6-miRNA blood signature for Parkinson\u2019s disease: from MPTP mice to human PBMC and serum exosomes. Front Neurol 16:1704976. https:\/\/doi.org\/10.3389\/fneur.2025.1704976","journal-title":"Front Neurol"},{"key":"6207_CR127","doi-asserted-by":"publisher","unstructured":"Kapplingattu SV, Bhattacharya S, Adlakha YK (n.d.) MiRNAs as major players in brain health and disease: current knowledge and future perspectives. Cell Death Discov [Internet]. https:\/\/doi.org\/10.1038\/s41420-024-02283-x.","DOI":"10.1038\/s41420-024-02283-x"},{"key":"6207_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2014.06.043","author":"BD Adams","year":"2014","unstructured":"Adams BD, Kasinski AL, Slack FJ (2014) Aberrant regulation and function of microRNAs in cancer. Curr Biol. https:\/\/doi.org\/10.1016\/j.cub.2014.06.043","journal-title":"Curr Biol"},{"key":"6207_CR129","doi-asserted-by":"publisher","unstructured":"Li Z, Zheng Z, Ruan J, Li Z, Tzeng CM (2016) Chronic inflammation links cancer and Parkinson\u2019s disease. Front Aging Neurosci 8(Jun). https:\/\/doi.org\/10.3389\/fnagi.2016.00126","DOI":"10.3389\/fnagi.2016.00126"},{"key":"6207_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00684-6","author":"MG Tansey","year":"2022","unstructured":"Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V (2022) Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/s41577-022-00684-6","journal-title":"Nat Rev Immunol"},{"key":"6207_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC (2017) NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/sigtrans.2017.23","journal-title":"Signal Transduct Target Ther"},{"key":"6207_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.12.012","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Lenardo MJ, Baltimore D (2017) 30 years of NF-\u03baB: a blossoming of relevance to human pathobiology. Cell. https:\/\/doi.org\/10.1016\/j.cell.2016.12.012","journal-title":"Cell"},{"key":"6207_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00312-6","author":"H Yu","year":"2020","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H (2020) Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-020-00312-6","journal-title":"Signal Transduct Target Ther"},{"key":"6207_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/nri1703","author":"M Karin","year":"2005","unstructured":"Karin M, Greten FR (2005) NF-\u03baB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/nri1703","journal-title":"Nat Rev Immunol"},{"key":"6207_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025","author":"S Grivennikov","year":"2010","unstructured":"Grivennikov S, Greten F, Karin M (2010) Immunity, inflammation, and cancer. Cell. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025","journal-title":"Cell"},{"key":"6207_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10481","author":"S Hunot","year":"2003","unstructured":"Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson\u2019s disease. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.10481","journal-title":"Ann Neurol"},{"issue":"5","key":"6207_CR137","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/BF01119794","volume":"9","author":"GB Elion","year":"1989","unstructured":"Elion GB (1989) The purine path to chemotherapy. Biosci Rep 9(5):509\u201329. https:\/\/doi.org\/10.1007\/BF01119794","journal-title":"Biosci Rep"},{"key":"6207_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00386-2","author":"JC Greenland","year":"2026","unstructured":"Greenland JC, Dresser K, Cutting E, Donegan R, Bond S, Crisp SJ, Scott KM, Voysey ZJ (2026) Azathioprine for the treatment of early Parkinson\u2019s disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(25)00386-2","journal-title":"Lancet Neurol"},{"key":"6207_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.01.018","author":"RS Wijeyekoon","year":"2020","unstructured":"Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Kuan WL, Evans JR, Breen DP (2020) Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson\u2019s disease. Brain Behav Immun. https:\/\/doi.org\/10.1016\/j.bbi.2020.01.018","journal-title":"Brain Behav Immun"},{"key":"6207_CR140","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040527","volume":"10","author":"JC Greenland","year":"2020","unstructured":"Greenland JC, Cutting E, Kadyan S, Bond S, Chhabra A, Williams-Gray CH (2020) Azathioprine immunosuppression and disease modification in Parkinson\u2019s disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ Open 10. https:\/\/doi.org\/10.1136\/bmjopen-2020-040527","journal-title":"BMJ Open"},{"issue":"13","key":"6207_CR141","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/mds.21552","volume":"22","author":"AL Bartels","year":"2007","unstructured":"Bartels AL, Leenders KL (2007) Neuroinflammation in the pathophysiology of Parkinson\u2019s disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord 22(13):1852\u20131856. https:\/\/doi.org\/10.1002\/mds.21552","journal-title":"Mov Disord"},{"issue":"8","key":"6207_CR142","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology 38(8):1285\u201391. https:\/\/doi.org\/10.1212\/WNL.38.8.1285","journal-title":"Neurology"},{"key":"6207_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(09)70062-6","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol. https:\/\/doi.org\/10.1016\/s1474-4422(09)70062-6","journal-title":"Lancet Neurol"},{"key":"6207_CR144","unstructured":"Cardiovascular toxicities of targeted therapy [Internet]. Oncohema Key. [cited 2026 Jun 29]. Available from: https:\/\/oncohemakey.com\/cardiovascular-toxicities-of-targeted-therapy\/. Accessed 10 June 2026"},{"key":"6207_CR145","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2640342","volume":"2018","author":"A Kezic","year":"2018","unstructured":"Kezic A, Popovic L, Lalic K (2018) MTOR inhibitor therapy and metabolic consequences: where do we stand? Oxid Med Cell Longev 2018. https:\/\/doi.org\/10.1155\/2018\/2640342","journal-title":"Oxid Med Cell Longev"},{"key":"6207_CR146","unstructured":"Bortezomib (2017) In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Accessed 12 June 2026"},{"issue":"7","key":"6207_CR147","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1515\/revneuro-2022-0093","volume":"34","author":"LY Li","year":"2023","unstructured":"Li LY, Liu SF, Zhuang JL, Li MM, Huang ZP, Chen YH et al (2023) Recent research progress on metabolic syndrome and risk of Parkinson\u2019s disease. Rev Neurosci 34(7):719\u2013735. https:\/\/doi.org\/10.1515\/revneuro-2022-0093","journal-title":"Rev Neurosci"},{"key":"6207_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/frdem.2024.1458038","volume":"3","author":"M Stevenson","year":"2024","unstructured":"Stevenson M, Algarzae NK, Moussa C (2024) Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes. Front Dement 3. https:\/\/doi.org\/10.3389\/frdem.2024.1458038","journal-title":"Front Dement"},{"issue":"12","key":"6207_CR149","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.3390\/cells10123547","volume":"10","author":"SR Bonam","year":"2021","unstructured":"Bonam SR, Tranchant C, Muller S (2021) Autophagy-lysosomal pathway as potential therapeutic target in Parkinson\u2019s disease. Cells 10(12):3547. https:\/\/doi.org\/10.3390\/cells10123547","journal-title":"Cells"},{"issue":"7","key":"6207_CR150","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/17425255.2025.2503848","volume":"21","author":"AA Mangoni","year":"2025","unstructured":"Mangoni AA, Woodman RJ, Jarmuzewska EA (2025) Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far. Expert Opin Drug Metab Toxicol 21(7):811\u2013829. https:\/\/doi.org\/10.1080\/17425255.2025.2503848","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"6207_CR151","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/mds.23148","volume":"25","author":"BJ Snow","year":"2010","unstructured":"Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O\u2019Sullivan JD, Fung V et al (2010) A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson\u2019s disease. Mov Disord 25(11):1670\u20131674. https:\/\/doi.org\/10.1002\/mds.23148","journal-title":"Mov Disord"},{"issue":"3","key":"6207_CR152","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s43587-026-01084-4","volume":"6","author":"MH Werner","year":"2026","unstructured":"Werner MH, McGarry A, Meyer C, Mancino E, Klint C, Pellecchia J et al (2026) The 201 trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson\u2019s disease. Nat Aging 6(3):626\u2013635. https:\/\/doi.org\/10.1038\/s43587-026-01084-4","journal-title":"Nat Aging"},{"key":"6207_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1628876","volume":"16","author":"J Song","year":"2025","unstructured":"Song J, Park SJ, Kim YJ, Park SM (2025) Nilotinib and imatinib: potential candidates for treatment of dementia and Parkinson\u2019s disease through national health insurance data. Front Neurol 16. https:\/\/doi.org\/10.3389\/fneur.2025.1628876","journal-title":"Front Neurol"},{"issue":"9","key":"6207_CR154","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/bph.14623","volume":"176","author":"M Khalifeh","year":"2019","unstructured":"Khalifeh M, Barreto GE, Sahebkar A (2019) Trehalose as a promising therapeutic candidate for the treatment of Parkinson\u2019s disease. Br J Pharmacol 176(9):1173\u20131189. https:\/\/doi.org\/10.1111\/bph.14623","journal-title":"Br J Pharmacol"},{"issue":"3","key":"6207_CR155","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/1568015023357950","volume":"2","author":"J Kreuter","year":"2002","unstructured":"Kreuter J (2002) Transport of drugs across the blood-brain barrier by nanoparticles. Curr Med Chem Cent Nerv Syst Agents 2(3):241\u2013249. https:\/\/doi.org\/10.2174\/1568015023357950","journal-title":"Curr Med Chem Cent Nerv Syst Agents"},{"key":"6207_CR156","doi-asserted-by":"publisher","first-page":"238428","DOI":"10.1155\/2013\/238428","volume":"2013","author":"M Masserini","year":"2013","unstructured":"Masserini M (2013) Nanoparticles for brain drug delivery. Int Sch Res Notices 2013:238428. https:\/\/doi.org\/10.1155\/2013\/238428","journal-title":"Int Sch Res Notices"},{"key":"6207_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1807","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. https:\/\/doi.org\/10.1038\/nbt.1807","journal-title":"Nat Biotechnol"},{"key":"6207_CR158","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jconrel.2018.08.035","volume":"287","author":"M Qu","year":"2018","unstructured":"Qu M, Lin Q, Huang L, Fu Y, Wang L, He S, Fu Y, Yang S, Zhang Z, Zhang L, Sun X (2018) Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson\u2019s disease. J Control Release 287:156\u201366. https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.035","journal-title":"J Control Release"},{"key":"6207_CR159","doi-asserted-by":"publisher","unstructured":"Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, J\u00e4rvinen T, Savolainen J (2008) Prodrugs: design and clinical applications. Nat Rev Drug Discov [Internet].\u00a0https:\/\/doi.org\/10.1038\/nrd2468","DOI":"10.1038\/nrd2468"},{"issue":"Suppl 3","key":"6207_CR160","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","volume":"9","author":"LR Hanson","year":"2008","unstructured":"Hanson LR, Frey WH (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9(Suppl 3):S5. https:\/\/doi.org\/10.1186\/1471-2202-9-S3-S5","journal-title":"BMC Neurosci"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06207-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:37:00Z","timestamp":1789569420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06207-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":160,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6207"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06207-x","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"899"}}